SS
CLDI icon

Steve Schonfeld’s Calidi Biotherapeutics CLDI Stock Holding History

Steve Schonfeld’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14
Closed -$274K – 2980
2022
Q2 		$274K Hold
14
– – ﹤0.01% 1723
2022
Q1 		$270K Buy
+14
New +$265K ﹤0.01% 1745

Other funds holding CLDI

DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $473M AUM 0.79% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

Steve Schonfeld's CLDI Position: Q3 2022 in Review

Steve Schonfeld sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 14 shares — an estimated $274K sold.

Steve Schonfeld first reported a position in CLDI in Q1 2022 and held it in 2 quarters. The position peaked at $274K in Q2 2022. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

  • Steve Schonfeld reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Steve Schonfeld sold 14 Calidi Biotherapeutics shares in Q3 2022, an estimated $274K.
  • Steve Schonfeld first reported a position in Calidi Biotherapeutics in Q1 2022 and held it in 2 quarters.
  • Steve Schonfeld's Calidi Biotherapeutics position peaked at $274K in Q2 2022.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.